Ac225merkattuja

Ac225merkattuja is a specialized database and collaborative network established in 2018 to catalogue and share information on Americium‑225 (^225Ac) samples that have been evaluated, purified, and documented for scientific and medical use. The initiative was launched by the International Atomic Energy Agency (IAEA) in partnership with national radiation safety agencies and academic institutions in Europe, North America, and Asia. Its primary purpose is to provide a centralized reference for researchers working with ^225Ac, a medically important alpha‑emitting radionuclide used in targeted alpha therapy for cancer treatment.

The database contains detailed entries for each labeled sample, including source laboratory, preparation method, chemical and radioactive purity, specific activity, decay data, and any variations in isotopic composition. Users can search for samples by origin, production technique, or half‑life, and can also submit new listings following standardized documentation protocols. All data entries undergo peer‑review by a committee of nuclear chemists and medical physicists before publication to ensure accuracy and reproducibility.

Security and compliance with international non‑proliferation regulations are core features of the platform. Each entry includes information on containment protocols, transport licensing, and regulatory permissions required for handling two‑million‑curie‑equivalent quantities of ^225Ac. Regular audits and updates keep the database current with evolving safety standards.

In addition to providing raw data, Ac225merkattuja hosts a series of webinars and best‑practice guides on handling, disposal, and integration of ^225Ac into research workflows. The network is instrumental in advancing targeted alpha therapy research, reducing redundancy in sample preparation, and fostering collaboration across the global nuclear medicine community.